Cargando…
P855: FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA
Autores principales: | La Spina, Enrico, Romano, Alessandra, Tibullo, Daniele, Giallongo, Cesarina, Scandura, Grazia, Cambria, Daniela, Giallongo, Sebastiano, Giuseppe Alberto, Palumbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431004/ http://dx.doi.org/10.1097/01.HS9.0000970324.85006.80 |
Ejemplares similares
-
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020) -
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
por: Palumbo, Giuseppe A., et al.
Publicado: (2023) -
P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA
por: Giallongo, C., et al.
Publicado: (2023) -
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023) -
TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
por: Scandura, Grazia, et al.
Publicado: (2022)